

Azithromycin

S

Elevated transaminase levels during off-label treatment: case report

A 27-year-old man developed elevated transaminase levels during off-label treatment with azithromycin for SARS-CoV-2 infection.

The man was diagnosed with a SARS-CoV-2 infection, in April 2020. His Liver examination revealed that alanine aminotransferase (ALT) at 4.4 times upper limit of normal (ULN), aspartate aminotransferase (AST) at 2.04 times ULN, GGT at 1.4 times ULN. He was admitted. He started receiving off label treatment with low-dose azithromycin [*dosage and route not stated*] and hydroxychloroquine. He started receiving tenofovir. At day 18 of admission, his ALT level was elevated to be 6 times ULN and AST level was 2.74 times ULN. He was admitted for 35 days. At discharge, his liver function tests was improved with a decrease in transaminase levels, ALT levels were 3.66 times ULN and AST levels were 1.44 times ULN. In July 2020, he had a normal liver function test with a negative viral load.

M'bodj K, et al. What would be the impact of covid-19 on liver function of a patient with chronic hepatitis b? About a case and literature review. Pan African Medical Journal 38: 225, Mar 2021. Available from: URL: <http://doi.org/10.11604/pamj.2021.38.225.28123>

803561782